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Protocol
AbstrAct
Introduction Many patients with asthma remain poorly 
controlled despite the use of inhaled corticosteroids 
and long-acting beta agonists. Poor control may arise 
from inadequate adherence, incorrect inhaler technique 
or because the condition is refractory. Without having 
an objective assessment of adherence, clinicians may 
inadvertently add extra medication instead of addressing 
adherence. This study aims to assess if incorporating 
objectively recorded adherence from the Inhaler Compliance 
Assessment (INCA) device and lung function into clinical 
decision making provides more cost-effective prescribing 
and improves outcomes.
Methods and analysis This prospective, randomised, 
multicentre study will compare the impact of using 
information on adherence to influence asthma treatment. 
Patients with severe uncontrolled asthma will be included. 
Data on adherence, inhaler technique and electronically 
recorded peak expiratory flow rate will be used to promote 
adherence and guide a clinical decision protocol to guide 
management in the active group. The control group 
will receive standard inhaler and adherence education. 
Medications will be adjusted using a protocol based on 
Global Initiativefor Asthma (GINA) recommendations. The 
primary outcome is the between-group difference in the 
proportion of patients who have refractory disease and are 
prescribed appropriate medications at the end of 32 weeks. 
A co-primary outcome is the difference between groups in 
the rate of adherence to salmeterol/fluticasone inhaler over 
the last 12 weeks. Secondary outcomes include changes in 
symptoms, lung function, type-2 cytokine biomarkers and 
clinical outcomes between both groups. Cost-effectiveness 
and cost-utility analyses of the INCA device intervention 
will be performed. The economic impact of a national 
implementation of the INCA-SUN programme will be 
evaluated.
Ethics and dissemination The results of the study will be 
published as a manuscript in peer-reviewed journals. The 
study has been approved by the ethics committees in the 
five participating hospitals.
Trial registration NCT02307669; Pre-results.
Strengths and limitations of this study
 ► In this randomised controlled study, the use of 
Inhaler Compliance Assessment (INCA) device 
adherence data in association with the biomarkers 
will be used to interpret changes in symptoms 
and lung function and hence characterise patients 
into different inflammatory phenotypes, enabling 
appropriate biological therapy.
 ► This study will use objectively measured adherence 
using the INCATM device to influence clinical decision 
making in the management of severe uncontrolled 
asthma.
 ► A limitation of the study is that the overall adherence 
for both groups will probably be higher than in the 
normal clinical practice setting because of provision 
of free inhalers and frequent visits.
 ► Frequent study visits allow more contact with 
healthcare providers and hence the patient-related 
outcomes such as asthma control test, Asthma 
Quality of Life Questionnaire and EQ-5D-3L scores 
and Work Productivity and Activity Impairment-
Asthma - are likely to improve.
 ► Another limitation to the study is the short duration 
(32 week duration) of the study which may show 
limited persistence of adherence; however, in a prior 
3 month randomised controlled trial, (NCT01529697), 
we showed that repeated feedback to the individual 
on their inhaler use, inhaler technique and habit 
formation significantly increased actual adherence 
in patients with severe uncontrolled asthma.
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InTroducTIon
In most patients with asthma, symptoms are controlled by 
regular use of inhaled corticosteroids and beta agonists. 
Despite availability of these medications, about 10–40% 
of patients remain uncontrolled.1 Prior to escalating 
therapy, a comprehensive asthma management strategy 
includes confirming the diagnosis, ensuring there are no 
unrecognised or untreated comorbidities and assessing 
and addressing adherence to inhaled therapy, including 
correct technique.2 3 A challenge to implementing this 
strategy is that, in asthma, between visits little objective 
evidence exists of the patient’s clinical course or their 
adherence to therapy. Good inhaler adherence includes 
taking the correct number of doses at the correct time 
and with good inhaler technique. In this study, we will 
use the Inhaler Compliance Assessment (INCATM) audio 
recording device,4–8 which is attached to patient’s inhalers 
and electronically records when the inhaler is being used. 
The INCA device can only be used with Diskus Dry Powder 
Inhalers; however, the device is currently being developed 
for several other inhaler devices. Analysis of the digital 
audio recordings from the INCA enables objective assess-
ment of both patients’ habit and technique of inhaler 
use4–8 and allows patient-tailored adherence enhancing 
interventions.9
In a previous study,10 we have shown that calculating 
adherence using a method which incorporates the 
interval between doses and inhaler technique is more 
reflective of changes in quality of life and lung function 
compared with other electronic measures of adherence 
described in the literature. This new method of calcu-
lating adherence is calculated as the area under the curve 
(AUC) using the trapezoid formula. This work has been 
previously described in detail.10–12 In this study, we aim 
to use that information to influence clinician’s decision 
in making changes to asthma medications. This has not 
been done in the previous studies,13 14 using the INCATM 
device.
In a prior randomised, controlled trial14 15 
(NCT01529697), we showed that repeated feedback to 
the individual on their inhaler use, inhaler technique and 
habit formation increased actual adherence in patients 
with severe, uncontrolled asthma. Actual adherence was 
74% (95% CI: 69 to 77) in the active group (INCATM feed-
back) and 64% (95% CI: 57 to 70) in the control group 
(p<0.01). At the end of the 3 month study, 65 of the 197 
(33%) patients had uncontrolled asthma. Among those 
withuncontrolled asthma, only 24 (12% of all patients) 
had good adherence. In contrast, 41 (21% of all patients) 
were poorly adherent, with a mean adherence of 51.8%. 
If a clinician had not known this prior poor adherence, 
an assumption that patients were refractory would have 
been made. Similarly, relying on self-reported symptoms, 
as opposed to objectively recorded lung function, would 
be misleading. We hypothesised that digitally recorded 
adherence, inhaler technique and peak expiratory flow 
rate (PEFR) information would be advantageous if used 
by clinicians when deciding to step up or step down 
therapy.
Recent data using inflammatory biomarkers have 
confirmed disease heterogeneity in asthma demon-
strating that up to 50% of patients with symptomatic 
asthma do not have typical eosinophilic airway inflam-
mation driven by T2 cytokines, termed as ‘Type2-Low 
asthma’, with minimal response to steroid therapy.16–19 
Understanding background inflammatory biology is 
important to interpret changes in symptoms and lung 
function when adherence is improved, particularly with 
inhaled steroids as some patients will have differential 
responses to improved adherence depending on the 
background inflammatory phenotype. Hence, parallel, 
accurate determination of an individual’s inflammatory 
phenotype may help direct appropriate asthma therapy.
We describe the protocol of a study of patients with 
severe, uncontrolled asthma attending specialist hospital 
asthma clinics in Ireland and Northern Ireland. The first 
phase of the study will involve nurse-led asthma training 
and inhaler education to improve adherence. The active 
group will receive INCATM feedback education, on their 
use of salmeterol/fluticasone and beta agonist reliever use, 
and electronic PEFR data. The control group will receive 
guideline-recommended asthma education and clinical 
monitoring. The second phase of the study involves medi-
cation adjustment by a clinician. The control group will 
undergo only the GINA-recommended cycle of review 
and medication change. For the active group, we will use 
the GINA-recommended cycle of review and medication 
change, but, in addition, it will be supplemented by objec-
tive integration of information on adherence and digitally 
recorded PEFR. Adherence will be assessed objectively 
in both groups using the INCATM electronic recording 
device over 32 weeks. Outcomes will be quantified using 
clinical, lung function, adherence and exacerbation data 
collected during the study period. This protocol paper 
is presented in accordance with the SPIRIT protocol 
guidelines (see oline supplementary file SPIRIT_Fillable_
INCA-SUN_210217).
MeThods and analysIs
objectives
The study aims to assess if a clinician’s knowledge of 
objectively measured adherence and PEFR influences 
the decisions that a clinician makes when they use the 
GINA-recommended cycle of review and medication 
change. We also aim to assess if feedback to the patient 
on their adherence using the INCATM and aligning this 
information to electronically recorded PEFR data lead to 
maintenance of adherence and inhaler technique.
study design
This is a multicentre, parallel group, prospective 
randomised controlled study; the flow of the study is 
shown in figure 1.
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study setting
The study is being conducted at the clinical research 
centres attached to specialist hospital asthma clinics of 
five university hospitals inthe Republic of Ireland and 
Northern Ireland. The study period is from 30 October 
2015 with ongoing recruitment.
eligibility criteria for study participants
Eligible patients must have a confirmed diagnosis of 
asthma, which is defined as a clinician diagnosis of 
asthma supported by any one of the following character-
istics: forced expiratory volume in 1 s (FEV1)/forced vital 
capacity <70% and FEV1 <80%, or a 12% improvement in 
FEV1 post bronchodilator, or a positive bronchial provo-
cation test or variability in diurnal PEFR of ≥15% over a 
1 month period.
In addition, patients eligible for the study must be 18 
years or older and must be managed with therapy consis-
tent with Stage 3–5 of the GINA guidelines.20 Patients 
must be characterised as having uncontrolled asthma at 
recruitment, which is defined as an asthma control test 
(ACT) ≤19. They must have been treated with ≥1 courses 
of oral corticosteroids for an asthma exacerbation in 
the prior year or have a history of a hospitalisation or 
emergency department attendance with an asthma exac-
erbation in the last year. Eligible patients must be capable 
of understanding and complying with the require-
ments of the protocol, including the ability to attend all 
required visits, and be willing to give voluntary informed 
consent prior to any protocol-specific procedures being 
performed. Patients must be able and willing to take 
inhaled medication and should be suitable for or already 
using a diskus inhaler.
exclusion criteria
Patients who are smokers or ex-smokers with >20 pack 
year history of smoking and those who are pregnant or 
intending to become pregnant are not eligible for the 
study. Additional exclusion criteria are those who are 
currently on biological treatment, specific concurrent 
potent cytochrome P4503A4 medications. Patients who 
have prior hypersensitivity to salmeterol/ fluticasone or 
fluticasone propionate or salbutamol are also not eligible 
for the study. Patients who have known significant concur-
rent medical disease that might mean that the participant 
cannot complete the full duration of the study will not be 
enrolled. 
Primary outcome
The study has two co-primary endpoints. The first co-pri-
mary endpoint will be the between-group difference in 
appropriate asthma medication prescription at the end of 
the study. In this case, appropriate refers to therapy after 
two GINA-recommended cycles of review and medication 
changes with prior knowledge of adherence. The exact 
steps in the clinical care decision pathway are outlined in 
Appendices 1–8. The other co-primary endpoint will be 
maintenance of actual adherence (defined as the combi-
nation of the time of use, interval between doses and 
critical errors; which is calculated as the AUC).10–12 21 This 
will be assessed by the between-group (active and control) 
difference in the mean of actual adherence to twice daily 
salmeterol/fluticasone use over the last 12 weeks of the 
study.
secondary outcomes
Secondary outcomes include clinical outcomes, 
patient-reported outcomes and economic outcomes 
(outlined in box 1). For each of the outcomes, unless 
otherwise stated, the differences (proportions, means, 
etc.) between the active and control groups will be calcu-
lated and compared for two time periods–the first 8 weeks 
and additionally the last 12 weeks of the study.
IncaTM device and analysis of the audio data
The trade marked INCATM device was designed at the 
Department of Bioengineering, Trinity College Dublin, 
Ireland. It was (CE)marked and manufactured by Vita-
lograph, Ennis, Ireland. Digital recordings will be 
performed as previously described.4–8 The audio record-
ings include information on critical inhaler errors such 
as: whether the device was primed, whether the patient 
exhaled after priming but before inhalation, whether 
an adequate flow rate was achieved, the exact flow rate, 
whether there were multiple inhalations indicating inad-
equate breath-holds and correct sequence of events/
Figure 1 The study flow. Phase I of the study involves patient education and development of goals; phase II involves 
physician–patient review focusing on implementing management changes based on these goals and the patient’s clinical 
course. GINA, Global Initiative for Asthma; INCA, Inhaler Compliance Assessment. 
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timing of events. The INCA audio recordings have been 
analysed for precision and accuracy in detecting inhaler 
technique errors by trained audio raters.4 8 22–24
enrolment, run-in phase and randomisation
Patients will be enrolled at specialist asthma clinics. 
Sources of referrals will extend to patients with asthma 
attending emergency departments or admitted to hospital 
wards. Each patient will attend for six visits in total over 
a 32 week period (see table 1). In the first week (run-in), 
the patient’s asthma response to inhaled steroids will be 
measured using a standardised 7 day FeNO and inhaled 
steroid challenge with adherence monitoring.25 Partic-
ipant retention will be promoted by a reminder phone 
call the day before the patient's visit.
Randomisation will take place at the end of the 7 day 
monitoring period, where patients will be randomised 
in an allocation ratio of 1:1 to active and control groups. 
Randomisation will be stratified by site and day 7 FeNO 
result (FeNO ≥45 ppb or FeNO <45 ppb). Allocation will 
be blocked using random permuted blocks of varying 
sizes of 2, 4 and 6. The randomisation schedule has been 
developed by a statistician and an independent clinical 
informatics manager using a computer-generated rando-
misation programme.
control group: behavioural intervention and inhaler training
In the control group, current best practice comprising 
adherence optimisation, asthma education, written 
action plans and inhaler training will be performed. 
The PEFR and the Inhaler Proficiency check-list Score 
(see online supplementary appendix 9) will be used to 
review and correct errors in inhaler technique. Each visit 
consultation will include: participant-identified goals 
for outcomes, exploration of barriers to achieving goals, 
explanation of the purpose of asthma treatment and 
provision of an asthma management plan. To promote 
adherence during the study, emphasis is put on the indi-
vidual developing a habit of using their inhaler at set times 
daily. At visits 4, 5 and 6, the patients will be reviewed by 
a physician who will review the ACT scores and PEFR 
data taken during the previous visits and this informa-
tion will be used to optimise patient treatment based 
on the designed physician script as detailed in online 
supplementary appendices 1–3. A video outlining inhaler 
education is available online.26
active group: feedback using recordings from the IncaTM
In the active intervention group, the educational inter-
vention involves using feedback on habit of use and 
inhaler technique analysis from the INCATM device to 
enhance patient’s adherence and guide further treat-
ment. As for the control group, each visit will include: 
participant-identified goals for outcomes, exploration of 
barriers to achieving goals, explanation of the purpose 
of asthma treatment and provision of an asthma manage-
ment plan. The consultation will also provide feedback on 
adherence (based on the analysis of the data presented 
in a graphical format; time of inhaler use, patterns of 
inhaler use and inhaler technique).14 The nurse will 
provide the patient with feedback on inhaler use timings 
and provide education on correcting inhaler technique 
errors using the analysis of information recorded on the 
INCATM device. The clinician will review the adherence 
data, electronic PEFR, ACT and clinical data and use 
this information to optimise patient treatment based on 
the designed physician script (see online supplementary 
appendices 4–8).
data collection, safety and confidentiality
Data will be collected on electronic and/or paper case 
record forms (CRFs). The patient’s name is retained only 
on the consent forms kept by the consultant and patient 
Box 1 Secondary endpoints
Secondary outcomes
Economic outcomes
 ► A cost-effectiveness and cost-utility analysis of the Inhaler 
Compliance Assessment (INCA) educational intervention compared 
with the control arm will be performed. In addition, an economic 
evaluation of a national implementation of the INCA-SUN programme 
will be conducted (budget impact analysis).
 ► To compare the average time lost to work between the active and 
control groups.
Patient-reported outcomes
 ► To compare the asthma control test (ACT), Asthma Quality of Life 
Questionnaire scores, EQ-5D-3L scores, Work Productivity and 
Activity Impairment-Asthma scores and peak expiratory flow rate 
(PEFR) between the active and control groups
Clinical outcomes
 ► To examine and compare the proportion of patients reaching stated 
clinical goals between the active and control groups.
 ► To compare the proportion of patients who are refractory, defined 
as having actual adherence ≥80%, ≥1 exacerbations, PEFR am/
pm <80% and ACT ≤19.
 ► To compare the proportion of patients who are non-adherent and 
remain uncontrolled, that is, actual adherence  <80%, PEFR am/
pm <80% and ACT ≤19.
 ► To compare the time to first exacerbation (defined by ≥20% fall in 
PEFR and at least doubling of reliever use for three consecutive days 
or prescribed rescue oral steroid) between the active and control 
groups.
 ► To compare the proportion of patients with inhaler-related side 
effects, including oral candidiasis, between the active and control 
groups.
 ► To compare changes in blood eosinophils, periostin and fractional 
exhaled nitric oxide (FeNO) between the active and control groups.
 ► To investigate the relationship of biomarker changes in relation to 
adherence.
 ► To compare the proportion of patients who were clinically stable 
(ie, proportion of patients who required no daily reliever use in the 
month prior to study end) between the active and control groups.
 ► To investigate the relationship between changes in FeNO 
(characterised into FeNO ≥45 ppb or FeNO <45 ppb) and adherence.
 ► To investigate the relationship between 7 day FeNO suppression and 
clinical and biomarker outcomes.
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tracking logs kept at the hospital. Safety monitoring will be 
conducted throughout the trial with reporting of adverse 
events (AEs) and serious adverse events (SAEs) in each 
participant’s CRF. All AEs/SAEs will be reported imme-
diately to the study principal investigator and attending 
physician. Each AE will be recorded separately. Causality 
will be determined by the investigator. Summary reports 
of medical AEs will be sent annually or at the end of the 
trial to ethics committees, investigators and the regula-
tory body; health products regulatory authority (HPRA). 
In the case of a SAE, the principal investigator, the HPRA 
and ethics committee must be informed as soon as 
possible after the site becomes aware of the incident.
At all times during the data collection process, patient 
confidentiality will be maintained by assigning a code 
number to each patient, which will be the only identifier 
on CRFs, diaries and quality of life(QOL) questionnaires. 
Data from patients at each site will be transferred to a 
secure electronic CRF which can be accessed only by 
authorised members of the Dublin centre for clinical 
research (DCCR)Pulmonary Group. CRFs will be kept for 
at least 3 years after termination of the study. Access to the 
web-based electronic CRF and database is by individual 
username and password. Each authorised user has access 
to view only data related to patients from that user's site 
and cannot see data relating to patients from other sites. 
Users’ access to patient data will be restricted to allow 
Add, Modify or Read-Only access to patient data. The 
tool has an inbuilt audit trail that records and can display 
details of additions or changes made to data, either on a 
by user or by patient basis.
Team organisation and data quality assurance
This project will be supervised and supported by the 
research team working with the principal investi-
gator (assumes responsibility for the conduct of the trial; 
responsible for medical care and decisions made on 
behalf of patients and prevent any unauthorised access 
to data) in the Royal College of Surgeons in Ireland 
(RCSI) Clinical Research Centre, Beaumont Hospital. In 
accordance with the lead centre policy for the conduct 
of investigator-led research, a project manager will be 
assigned to oversee the setting up and continued conduct 
of the trial, information and software manager (maintains 
functioning web server and electronic CRF) and study 
nurse and study doctor who are involved in providing 
study interventions/education and conducting the study 
visits. A data manager will be assigned to monitor data 
and ensure validity of the data during the duration of the 
study. A two-weekly lab meeting between the principal 
investigator, statistician, study project manager and data 
manager will be held, with monthly update meetings, via 
telephone and face to face will occur with the other sites. 
This group of individuals will be blinded to the treatment 
groups and will conduct an interim analysis of clinical 
outcome data for efficacy and data analysis for expected 
and unexpected AEs for safety once 50% of total patient 
recruitment is achieved. There will be a trial monitoring V
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committee which comprises of five international experts 
in asthma management, the local director of clinical 
research and a local quality, safety and regulatory officer.
Monitoring procedures
The lead centre RCSI will coordinate the study and will 
provide advice, education and support to the research 
staff at all participating sites. Each participating clinical 
research centre is required to endeavour to maximise data 
quality and to carry out any necessary audit that would be 
required to ensure data quality and integrity meet scien-
tific standards. An independent monitor will carry out 
monitoring visits to each site on at least one occasion and 
will ensure that the study is being conducted according 
to good clinical practice guidelines; ensure that the 
protocol has been adhered to; that all pertinent informa-
tion has been recorded; perform source data verification; 
monitor product accountability and ensure that all CRFs 
are complete and signed off by the investigator.
Post-trial care
At study completion, patients are prescribed an inhaler 
without the INCATM device attached and referred back to 
their primary respiratory physician. There are no known 
risks associated with using the INCATM device, but in the 
very unlikely event that a patient is harmed in any way 
during the duration of the study, the patients are covered 
by medical indemnity.
data dissemination and data sharing
At the end of the study period, all data generated or anal-
ysed during this study will be published as an article and 
supplementary appendix in relevant respiratory medi-
cine journals. The data will also be presented in national 
and international conferences. Requests for data sharing 
will be subject to approval from ethics committees of the 
participating hospitals.
Biomarkers
At each study visit, type-2 biomarkers (peripheral blood 
eosinophils, serum periostin and FeNO) will be measured 
to allow composite biomarker profiling which has been 
shown to better assess exacerbation risk in severe asthma 
and which is independent of symptoms and lung func-
tion.12 This will allow alignment with the UK Refractory 
Asthma Stratification Programme (http://www. rasp. 
org. uk/) and allow clinical outcomes to be related to 
biomarker profile and steroid responsiveness in all 
subsets.
Blinding
Neither the education provider (study nurse and study 
clinician) nor the patient will be blinded to the education 
intervention. To avoid the risk of contamination between 
the active group and the control group, the researchers 
delivering the education (best practice care) to the 
control group patients will not have access to the control 
patients INCATM data. The data outcome assessors will be 
blinded to study subject treatment allocation.
sample size
The sample size calculation is based on the two primary 
outcomes. Based on prior data in a similar cohort10 
(NCT01529697), we anticipate that the difference in the 
proportion of patients who will require step-up therapy 
in the active group will be 10% versus 30% in the control 
group (a difference of 20%). We estimate that a sample 
size of 164 (82 per group) will provide a power of 90% at 
a significance level of 0.05, accounting for a 10% dropout 
rate, to detect a difference of 20% between the groups.
For the second primary outcome, we anticipate that the 
baseline (visits 1–2) mean adherence will be 0.65 with a 
SD of 0.20. We expect a mean (SD) change from baseline 
to end of therapy of 0.15 (0.02) in the active group and a 
change of 0.05 (0.03) in the control group. Hence, using 
a two-sided alpha of 0.05, we estimate that 112 patients 
per treatment group (total: 224) will provide 80% power 
to detect a treatment difference of 0.10, assuming a 
combined SD of 0.25 and a 10% dropout rate.
On the basis of these calculations, we aim to recruit 112 
patients in each group, giving a total of 224 patients.
sTaTIsTIcal MeThods
data analysis
The primary analysis will be conducted on an intention-
to-treat (ITT) basis. Secondary, per-protocol analyses will 
also be performed. ITT analyses will include all patients 
randomised to the trial regardless of whether they have 
completed the study protocol or not. A per-protocol 
analysis will include patients who comply with >80% 
of the trial protocol. In the first stage of the analysis, 
descriptive statistics will be used to describe recruited 
individuals and to investigate comparability of the trial 
arms at baseline. The number of patients and percentage 
will be presented for categorical variables. For contin-
uous variables that are normally distributed, the mean 
and SD will be presented, while median and IQR will be 
presented for continuous variables that are not normally 
distributed.
For the comparison of the proportion of patients 
between control and active group prescribed inap-
propriate medication at the end of the study, a logistic 
regression model adjusting for stratification variables, 
with results presented as ORs, 95% CIs and p-values, will 
be used. Furthermore, the estimated costs associated with 
these prescriptions will be investigated. The full statis-
tical analysis plan is included (see online supplementary 
appendix 10).
To compare actual adherence,10–12 reported previ-
ously over the last 12 weeks of the study between the two 
groups, the primary analysis will be conducted on an 
ITT basis and adjusted for stratification variables (site 
and FeNO suppression). A linear regression model, with 
results presented as difference in means, 95% CIs and 
p-values, will be used. Further adjustment will be made 
for any variables displaying marked imbalance between 
the arms at baseline.
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dIscussIon
Most patients with asthma achieve symptom control 
and experience minimal exacerbations with regular 
controller treatment; however, some patients will not 
achieve these goals even with maximal asthma therapy.27 
In some patients, this is due to refractory severe asthma, 
but in many others, it is due to ‘difficult to treat asthma’, 
whereby there are untreated comorbidities, persistent 
environmental exposures or psychosocial factors and 
suboptimal intentional or unintentional adherence. 
Distinguishing patients with refractory asthma from 
patients with ‘difficult to treat asthma’ requires objec-
tive information on adherence and lung function. It is 
expected that during this study many patients will become 
controlled and achieve their stated clinical goals, but 
that some will remain uncontrolled. By combining the 
clinical outcomes with the longitudinal adherence data, 
asthma control and PEFR data, we will test if a clinician 
is better equipped to optimise treatment than if they rely 
on self-report alone.
We will also assess biomarker data, adherence and 
changes in lung function. By relating the changes in adher-
ence and changes in biomarkers over the duration of the 
study period. we expect to be able to identify refractory 
patients who are persistently type 2 T-helper (Th2)- high 
despite being adherent. We will also better understand 
the outcome in subjects with Th2-low asthma, who may 
not have a significant improvement in clinical outcome 
despite better adherence as their disease is unlikely to 
respond to inhaled steroids. We will also potentially be 
able to assess longitudinal changes in symptoms and lung 
function and adherence in this population. Detailed 
analysis of these groups may provide insight into the 
relationship between inflammatory biology and changes 
in lung function, symptoms and exacerbations.28–31 We 
believe that our study will allow accurate alignment of an 
individual’s inflammatory phenotype with actual adher-
ence and therefore allow precise determination of those 
who are truly Th2-high or Th2-low for the first time.
conclusion
In summary, this study will assess if electronically recorded 
data, measured by the INCATM device, can be integrated 
and used to guide asthma management better than 
standard care. The study will explore if information on 
adherence reduces inappropriate prescribing. In addi-
tion, the study will provide insight into the long-term 
relationship of adherence with both digitally recorded 
lung function and type-2 cytokine biomarker profile. 
Future follow-up studies, using more pragmatic trial 
designs, could test the broader external usability in real-
world settings, including primary care and community 
pharmacy practice.
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